Evidence map›Paper›PMID 26354343›Full record

ArticleAnnals of laboratory medicine2015

Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.

Nuri Lee, Hyewon Lee, Soo Young Moon, Ji Yeon Sohn, Sang Mee Hwang, Ok Jin Yoon, Hye Sun Youn, Hyeon Seok Eom, Sun Young Kong

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of laboratory medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Nuri LeeDepartment of Laboratory Medicine, Center for Diagnostic Oncology, Hospital and Research Institute, National Cancer Center, Goyang, Korea.
Hyewon LeeHematologic Oncology Clinic, Center for Specific Organs Cancer, Hospital and Research Institute, National Cancer Center, Goyang, Korea.
Soo Young MoonDepartment of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea.
Ji Yeon SohnDepartment of Laboratory Medicine, Center for Diagnostic Oncology, Hospital and Research Institute, National Cancer Center, Goyang, Korea.
Sang Mee HwangDepartment of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Ok Jin YoonDepartment of Laboratory Medicine, Center for Diagnostic Oncology, Hospital and Research Institute, National Cancer Center, Goyang, Korea.
Hye Sun YounDepartment of Laboratory Medicine, Center for Diagnostic Oncology, Hospital and Research Institute, National Cancer Center, Goyang, Korea.
Hyeon Seok EomHematologic Oncology Clinic, Center for Specific Organs Cancer, Hospital and Research Institute, National Cancer Center, Goyang, Korea. hseom@ncc.re.kr.
Sun Young KongResearch Institute, Translational Epidemiology Branch, National Cancer Center, Goyang, Korea.
National Cancer Center · KRSeoul National University Bundang Hospital · KRSeoul National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAngiogenesis is important for the proliferation and survival of multiple myeloma (MM) cells. Bone marrow (BM) microvessel density (MVD) is a useful marker of angiogenesis and is determined by immunohistochemical staining with anti-CD34 antibody. This study investigated the prognostic impact of MVD and demonstrated the relationship between MVD and previously mentioned prognostic factors in patients with MM.

methodsThe study included 107 patients with MM. MVD was assessed at initial diagnosis in a blinded manner by two hematopathologists who examined three CD34-positive hot spots per patient and counted the number of vessels in BM samples. Patients were divided into three groups according to MVD tertiles. Cumulative progression-free survival (PFS) and overall survival (OS) curves, calculated by using Kaplan-Meier method, were compared among the three groups. Prognostic impact of MVD was assessed by calculating Cox proportional hazard ratio (HR).

resultsMedian MVDs in the three groups were 16.8, 33.9, and 54.7. MVDs were correlated with other prognostic factors, including β2-microglobulin concentration, plasma cell percentage in the BM, and cancer stage according to the International Staging System. Multivariate Cox regression analysis showed that high MVD was an independent predictor of PFS (HR=2.57; 95% confidence interval, 1.22-5.42; P=0.013). PFS was significantly lower in the high MVD group than in the low MVD group (P=0.025). However, no difference was observed in the OS (P=0.428).

conclusionsIncreased BM MVD is a marker of poor prognosis in patients newly diagnosed with MM. BM MVD should be assessed at the initial diagnosis of MM.

Indexed as

AgedAntigens, CD34Bone MarrowDisease-Free SurvivalFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleMicrovesselsMiddle AgedMultiple MyelomaNeoplasm StagingNeovascularization, PathologicPlasma CellsPrognosisAntigens, CD34AngiogenesisBone marrowCD34ImmunohistochemistryMicrovesselMultiple myelomaProgression-free survival

Identifiers

PMID26354343
PMCPMC4579099
OpenAlexW2107210315

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.